Merck said on Wednesday that its experimental oral HIV treatment was not inferior to Gilead's top-selling HIV drug Biktarvy ...
Merck MRK announced positive top-line results from a pivotal late-stage study evaluating its investigational, once-daily, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Funding for HIV care and prevention are key for continued progress, but recent cuts to federal funding for health agencies, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) to be held in Paris, France from October 15-18. As the leader in HIV ...
New diagnoses of HIV and syphilis have doubled in Florida since 2020. St. Lucie County has the highest rate of new HIV cases ...
Last year, 444 people in the Netherlands were diagnosed with HIV, the virus that can cause AIDS. Almost 20 years ago, there ...
Burlington Free Press on MSN
UVM joins major study on drug use and treatment barriers across New England
The initiative, funded by a $12 million grant from the National Institute on Drug Abuse, will evaluate how people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback